Abstracts Archive - Page 1757 of 2607 - ACR Meeting Abstracts

Abstract Number: 2372 • 2016 ACR/ARHP Annual Meeting
Effect of Oxytocin on Osteoarthritis
christian roux¹, astrid pinzano², didier Pisani³, Patricia panaia-Ferrari⁴, eric Fontas⁵, hedi Ben Yahia⁶, damien ambrosetti⁷, jean-François michiels⁸, veronique Breuil⁹ and ez Zoubir Amri¹⁰, ¹Rheumatology, LAMHESS laboratory, sofia antipolis university, CHU Pasteur 2, Nice, France, nice, France, ²IMoPA Ingénierie Moléculaire et Physiopathologie Articulaire, University nancy lorraine, UMR7365 CNRS-UL, Nancy, France, ³CNRS UMR7277, Inserm U1091, UNS Université Nice Sophia Antipolis Parc Valrose, nice, France, ⁴IBiology and immunology laboratory, university nice sofia antipolis, nice, France, ⁵Direction recherche clinique, CHU de Nice, france, Nice, France, ⁶iBV - Institut de Biologie Valrose. Nice, Nice, France, ⁷Department anatomopathology, nice. university nice sofia antipolis, nice, France, ⁸department anatomo-pathology, Nice, university nice sofia antipolis, Nice, France, ⁹Rheumatology department, Nice, France, ¹⁰CNRS UMR7277, Inserm U1091, UNS Université Nice Sophia Antipolis Parc Valrose, Nice, France
Background/Purpose: The relationship between oxytocine (OT) and osteoarthritis (OA) is poorly studied and remains unknown. However the subchondral bone is considered as a major player in…
Abstract Number: 2373 • 2016 ACR/ARHP Annual Meeting
Patient Preference for Display of Electronic Patient-Reported Outcomes in Osteoarthritis Clinical Trials: Wording Emphasis, Question Format, and Navigation Button Placement
Laura Khurana¹, Ellen Durand¹, Sarah Gary¹, Tony Otero¹, Chris Hall¹, Aisling Ryan², Christopher J. Evans² and Susan Dallabrida¹, ¹ERT, Boston, MA, ²Endpoint Outcomes, Boston, MA
Background/Purpose: Electronic patient-reported outcomes (ePROs) are a reliable method for collecting patient data in osteoarthritis clinical trials and offer many advantages over paper collection; however,…
Abstract Number: 2374 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis: Results from an Open-Label Long-Term Follow-up Study
Hermine I. Brunner¹, Nicolino Ruperto², Pierre Quartier³, Tamás Constantin², Ekaterina Alexeeva⁴, Rayfel Schneider¹, Isabelle Kone-Paut², Kenneth Schikler¹, Katherine Marzan¹, Nico Wulffraat⁴, Shai Padeh⁴, Vyacheslav Chasnyk², Carine Wouters⁴, Jasmin B. Kuemmerle-Deschner⁴, Tilmann Kallinich⁴, Bernard Lauwerys⁵, Elie Haddad¹, Evgeny L Nasonov⁴, Maria Trachana⁴, Olga Vougiouka⁴, Karolynn Leon⁶, Antonio Speziale⁷, Karine Lheritier⁷, Eleni Vritzali⁸, Daniel J Lovell¹, Alberto Martini² and PRINTO/PRCSG, ¹PRCSG, Cincinnati, OH, ²PRINTO-Istituto Gaslini, Genoa, Italy, ³Hôpital Necker-Enfants Malades, Paris, France, ⁴PRINTO-Istituto Gaslini, Genova, Italy, ⁵Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharma AG, Basel, Switzerland, ⁸Immunology and Dermatology Franchise, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Canakinumab (CAN), a highly selective human anti-IL1 β monoclonal antibody, had demonstrated its efficacy and safety in patients (pts) with active systemic juvenile idiopathic…
Abstract Number: 2375 • 2016 ACR/ARHP Annual Meeting
Biologic Therapy Modifies Clinical and Laboratory Features of Macrophage Activation Syndrome Associated with Systemic Juvenile Idiopathic Arthritis
Grant Schulert¹, Francesca Minoia², John F. Bohnsack³, Randy Q. Cron⁴, Soah Hashad⁵, Isabelle Koné-Paut⁶, Mikhail Kostik⁷, Daniel J Lovell⁸, Despoina Maritsi⁹, Peter A. Nigrovic¹⁰, Priyankar Pal¹¹, Angelo Ravelli², Masaki Shimizu¹², Valda Stanevicha¹³, Bas Vastert¹⁴, Fabrizio De Benedetti¹⁵ and Alexei Grom¹⁶, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Istituto Giannina Gaslini, Genoa, Italy, ³Division of Allergy, Immunology and Pediatric Rheumatology, University of Utah, Salt Lake City, UT, ⁴Pediatric Rheumatology, Children's Hospital of Alabama, Birmingham, AL, ⁵Tripoli Children's Hospital, Tripoli, Libya, ⁶Hopital Kremlin Bicetre, University of Paris SUD, Paris, France, ⁷Hospital Pediatrics, State Pediatric Medical University, Saint-Petersburg, Russia, ⁸PRCSG Cincinnati Children's Hospital Medical Center, Cinncinnati, OH, ⁹2nd Department of Academic Pediatrics, Athens Medical School, university of Athens, Athens, Greece, ¹⁰Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Boston, MA, ¹¹Institute of Child Health, Kolkata, India, ¹²Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan, ¹³Pediatric cathedra, Riga Stradiņš University, Riga, Latvia, ¹⁴Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Netherlands, ¹⁵Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy, ¹⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening episode of hyperinflammation and a substantial cause of morbidity and mortality in pediatric rheumatology. It occurs most…
Abstract Number: 2376 • 2016 ACR/ARHP Annual Meeting
The Disease Burden of Systemic Juvenile Idiopathic Arthritis for Patients and Caregivers: An International Health Related Quality of Life Survey and Retrospective Chart Review
Susan Shenoi¹, Gerd Horneff², Michal Cidon³, Athimalaipet Ramanan⁴, Yukiko Kimura⁵, Pierre Quartier⁶, Ivan Foeldvari⁷, Andrew Zeft⁸, Kathleen G Lomax⁹, Jill Gregson¹⁰, Sarah Campbell¹¹, Jeffrey Weiss¹¹, Nina Marinsek¹¹, Dony Patel¹¹ and Nico Wulffraat¹², ¹Seattle Children's Hospital, Seattle, WA, ²Asklepios Kliniken GmbH, Hamburg, Germany, ³Stanford University, Palo Alto, CA, ⁴University Hospitals Bristol, Bristol, United Kingdom, ⁵Hackensack University Medical Center, Hackensack, NJ, ⁶Hôpital Necker, Paris, France, ⁷Hamburger Zentrum für Kinder-und Jugend Rheumatologie, Hamburg, Germany, ⁸Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹Navigant Consulting, Inc., London, United Kingdom, ¹²Wilhelmina Kinderziekenhuis, Utrecht, Netherlands
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a severe autoinflammatory disease characterized by systemic features including high fevers, rash, and arthritis. SJIA can impose a…
Abstract Number: 2377 • 2016 ACR/ARHP Annual Meeting
Innovative Use of PK and PD to Guide Dose Selection for a Monoclonal Antibody Aimed at Neutralizing the High IFNγ Activity Present in Patients with Macrophage Activation Syndrome (MAS)
Philippe Jacqmin¹, Kathy de Graaf², Maria Ballabio², Robert Nelson², Zoë Johnson², Walter Ferlin², Geneviève Lapeyre², Fabrizio De Benedetti³ and Cristina de Min², ¹MnS, Dinant, Belgium, ²NovImmune S.A., Geneva, Switzerland, ³Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy
Background/Purpose: Data from an animal model of MAS and the observed high IFNγ and IFNγ-related chemokines (CXCL9, CXCL10) levels in MAS/sJIA patients have prompted the…
Abstract Number: 2378 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetic and Pharmacodynamic Characteristics of Canakinumab in Patients with Periodic Fever Syndromes: Results from a Phase III Pivotal Umbrella Trial
Joost Frenkel¹, Jordi Anton², Avi Livneh³, Eldad Ben-Chetrit⁴, Paul Brogan⁵, Segundo Bujan-Rivas⁶, Tamás Constantin⁷, Fabrizio De Benedetti⁸, Marco Gattorno⁹, Ahmet Gül¹⁰, Hal M. Hoffman¹¹, Isabelle Kone-Paut¹², Helen Lachmann¹³, Seza Ozen¹⁴, Anna Simon¹⁵, Jeroen Van der Hilst¹⁶, Andrew Zeft¹⁷, Antonio Speziale¹⁸, Guido Junge¹⁸ and Lucy Xu¹⁹, ¹University Medical Center,Utrecht, Utrecht, Netherlands, ²Hospital Sant Joan de Déu, Barcelona, Barcelona, Spain, ³Department of Medicine F, Sheba Medical Center, Tel Hashomer, Israel, ⁴Medicine A Rheum Unit, Hadassah University Hosp, Jerusalem, Israel, ⁵Department of Paediatric Rheumatology, UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁶Vall d'Hebron Hospital, Barcelona, Barcelona, Spain, ⁷Unit of Paediatric Rheumatology, 2nd Dpt of Pediatrics, Semmelweis University, Budapest, Hungary, ⁸Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy, ⁹UO Pediatria 2, Istituto Giannina Gaslini, Genova, Italy, ¹⁰Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ¹¹Pediatric Allergy, Immunology and Rheumatology, University of California at San Diego/Rady Children Hospital, La Jolla, CA, ¹²PRINTO, Genoa, Italy, ¹³UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ¹⁴Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁶Department of infectious disease and immunity, Jessa Hospital, Hasselt, Hasselt, Belgium, ¹⁷Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, ¹⁸Novartis Pharma AG, Basel, Switzerland, ¹⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: The pharmacokinetics (PK) of canakinumab (CAN) and total interleukin (IL)-1β kinetics have been well investigated in CAPS patients (pts).1 Here we present the PK…
Abstract Number: 2379 • 2016 ACR/ARHP Annual Meeting
Effect of Canakinumab Treatment on Health-Related Quality of Life in Patients with Periodic Fever Syndromes
Anna Simon¹, Anna Shcherbina², Jordi Anton³, Eldad Ben-Chetrit⁴, Fabrizio De Benedetti⁵, Joost Frenkel⁶, Marco Gattorno⁷, Ryoki Hara⁸, Philip J Hashkes⁹, Michaël Hofer¹⁰, Hal M. Hoffman¹¹, Isabelle Koné-Paut¹², Helen Lachmann¹³, Alberto Martini¹⁴, Seza Ozen¹⁵, Andrew Zeft¹⁶, Antonio Speziale¹⁷, Guido Junge¹⁷ and Jill Gregson¹⁷, ¹General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Clinical immunology Department, Center of Children's Hematology n.a. D. Rogachev, Moscow, Russian Federation, ³Hospital Sant Joan de Déu, Barcelona, Spain, ⁴Rheumatology Unit, Hadassah—Hebrew University Medical Center, Jerusalem, Israel, ⁵IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy, ⁶University Medical Center Utrecht, Utrecht, Netherlands, ⁷Pediatric Rheumatology, G. Gaslini Institute, Genoa, Italy, ⁸Yokohama City University, Yokohama, Japan, ⁹Pediatrics Rheumatology; Shaare-Zedek Medical Center, Jerusalem, Israel, ¹⁰Pediatric Rheumatology of Western Switzerland, CHUV, University of Lausanne, Lausanne, Switzerland, ¹¹University of California at San Diego, San Diego, CA, ¹²Hopital Kremlin Bicetre, University of Paris SUD, Paris, France, ¹³UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ¹⁴Istituto G. Gaslini Pediatria II Reumatologia, Genova, Italy, ¹⁵Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹⁶Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, ¹⁷Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Open label studies have shown the efficacy of canakinumab (CAN), a fully human and highly specific anti-IL-1β monoclonal antibody, in patients (pts) with Periodic…
Abstract Number: 2380 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Patients Aged One to Six Years with Cryopyrin-Associated Periodic Syndromes: Results of an Open-Label, Phase III Extension Study
Paul Brogan¹, Michaël Hofer², Jasmin B. Kuemmerle-Deschner³, Bernard Lauwerys⁴, Antonio Speziale⁵, Karolynn Leon⁶, Xiaoling Wei⁷ and Ronald Laxer⁸, ¹Department of Paediatric Rheumatology, UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ²Pediatrie, Unité Romande de Rhumatologie Pédiatrique, Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ³University Hospital Tuebingen, Tuebingen, Germany, ⁴Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Shanghai Novartis Trading Limited, Shanghai, China, ⁸The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Cryopyrin-Associated Periodic Syndrome (CAPS), is a rare hereditary auto inflammatory disorder representing 3 phenotypes: familial cold auto-inflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and chronic…
Abstract Number: 2381 • 2016 ACR/ARHP Annual Meeting
Canakinumab Monotherapy for the Treatment of Majeed Syndrome. Five-Year Experience
Mia Glerup¹, Bente Fiirgaard², Christian Høst³, Polly Ferguson⁴ and Troels Herlin⁵, ¹Pediatric Rheumatology Clinic, Department of Pediatrics, Dept. of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ²MR Research Centre, Aarhus University Hospital, Aarhus N, Denmark, ³Dept. of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ⁴Department of Pediatrics--Rheumatology, University of Iowa Carver College of Medicine, Iowa City, IA, ⁵Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus N, Denmark
Background/Purpose: Majeed syndrome is a rare, autosomal recessive disorder that presents with early onset chronic recurrent multifocal osteomyelitis (CRMO) and microcytic congenital dyserythropoietic anaemia caused…
Abstract Number: 2382 • 2016 ACR/ARHP Annual Meeting
Evaluation of Intestinal Inflammation in Children with FMF
Ozge Altug-Gucenmez, Tuncay Kume, Balahan Makay, Omur Babayigit, Nur Arslan and Erbil Unsal, Dokuz Eylul University, Izmir, Turkey
Background/Purpose: Familial Mediterranean Fever (FMF) is the most common auto-inflammatory disease with recurrent fever and serositis episodes. Abnormal pyrin protein due to MEFV gene mutations…
Abstract Number: 2383 • 2016 ACR/ARHP Annual Meeting
Analysis of the Use of Anticoagulants and Antiplatelet Agents in Strokes Caused By the Deficiency of Adenosine Deaminase 2
Patrycja Hoffmann¹, Amanda K. Ombrello², Deborah L. Stone¹, Karyl Barron³, Gineth Pinto-Patarroyo¹, Anne Jones¹, Tina Romeo⁴, Dean Follmann⁵, Camilo Toro⁶, Ariane Soldatos⁷, Qing Zhou⁸, Ivona Aksentijevich¹ and Daniel L. Kastner¹, ¹Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ²Inflammatory Diseases Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ⁴National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁵NIAID, Bethesda, MD, ⁶NIH Undiagnosed Diseases Program, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁷National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, ⁸Inflammatory Disease Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is a recessive genetic condition in which children develop recurrent strokes, intermittent fevers, elevated acute-phase reactants, livedoid rash,…
Abstract Number: 2384 • 2016 ACR/ARHP Annual Meeting
Variable Clinical Phenotypes and Relation of Interferon Signature with Disease Activity in ADA 2 Deficiency
Antonella Insalaco¹, Gianmarco Moneta², Manuela Pardeo¹, Chiara Passarelli³, Camilla Celani⁴, Virginia Messia⁴ and Fabrizio De Benedetti¹, ¹Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy, ²Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Roma, Italy, ³Ospedale Pediatrico Bambino Gesù IRCCS, Unit of Medical Genetics, Laboratory of Cytogenetics and Molecular Genetics, Rome, Italy, ⁴Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy
Background/Purpose: The deficiency of adenosindeaminase 2 (DADA2) is a recently described autosomal recessive autoinflammatory disease, caused by mutations of CECR1 and characterized by early onset…
Abstract Number: 2385 • 2016 ACR/ARHP Annual Meeting
Validation of Diary Score for the Assessment of Disease Activity in Candle (Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature) and SAVI (STING associated vasculopathy with onset in Infancy) Patients
Megha Sawhney¹, Gina A. Montealegre Sanchez², Robert Wesley³, Kost Bahar¹ and Raphaela Goldbach-Mansky⁴, ¹NIAMS, National Institutes of Health, Bethesda, MD, ²National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ³Clinical Center, National Institutes of Health, Bethesda, MD, ⁴Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
Background/Purpose: CANDLE and SAVI are two rare autoinflammatory interferonopathies without validated outcome measures to assess disease activity; however, daily diaries of prominent disease symptoms have…
Abstract Number: 2386 • 2016 ACR/ARHP Annual Meeting
Role of Pentraxin 3 in Patients with Juvenile Scleroderma
Amra Adrovic¹, Sezgin Sahin¹, Kenan Barut¹, Sinem Durmus², Hafize Uzun² and Ozgur Kasapcopur³, ¹Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, ²Biochemistry, Istanbul University, Cerrahpasa Medical School, Department of Biochemistry, Istanbul, Turkey, ³Department of Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey
Background/Purpose: Juvenile scleroderma (JS) is a rarely seen chronic connective tissue disorder. According to organ involvement, the disease is divided into two main forms: systemic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].